Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Adhesion G protein-coupled receptor L4 |
| Gene Name | ADGRL4 |
| Uniprot | Q9HBW9 (Human); Q923X1 (Mouse) |
| Synonym | ETL; ELTD1; KPG_003; EGF, latrophilin and seven transmembrane domain containing 1; EGF, latrophilin and seven transmembrane domain-containing protein 1; EGF-TM7-latrophilin-related protein |
| Background | Adhesion G protein-coupled receptor L4 (ADGRL4), also known as ETL, ELTD1 or KPG_003, is encoded by the ELTD1 gene. Based on its sequence, ADGRL4 is a member of the secretin family of G protein-coupled peptide hormone receptors and belongs to the epidermal growth factor 7-transmembrane (EGF-TM7) subfamily. ADGRL4 plays a role in angiogenesis, both physiological and pathological, as well as glioblastoma and the protein levels of ADGRL4 are significantly higher in humans and rodent gliomas. Structurally, it contains a large extracellular domain with EGF-like repeats, a seven transmembrane domain, and a short cytoplasmic tail. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX303 | NativeExtract™ Human ADGRL4 Membrane Protein (Full length, Super Nanodisc) | HEK293 cell | Full length | Native Nanodisc |
| MPX3651K | MemDX™ Membrane Protein Human ADGRL4 Expressed in vitro E.coli expression system, Full Length of Mature Protein | E.coli cell-free | Full length | Detergent |
| Please for more products or customization | ||||
A**x: Their tailored ADGRL4 service delivered precise post-translational modifications and solubilization.
28/Jun/2023
R***y: The technical team provided rapid optimization guidance.
06/Dec/2023
ADGRL4 Gene Therapy Development
We provide tailored solutions to meet your specific requirements. Please for more services.
ADGRL4 Gene Knockout for Angiogenesis Modulation
Creative Biolabs offers gene knockout services for angiogenesis modulation. ADGRL4, a critical regulator of tumor angiogenesis, presents a compelling target for gene-editing strategies. Preclinical studies in murine xenograft models have demonstrated that ADGRL4 knockout reduces VEGF-A signaling and tumor vascularization by >60%. Creative Biolabs' proprietary lentiviral vectors, engineered for endothelial-specific tropism, enable efficient delivery of gene-editing components to target tissues.
AAV-Driven ADGRL4 shRNA Knockdown
Creative Biolabs offers AAV-driven ADGRL4 shRNA knockdown services. Adeno-associated viral (AAV) vectors expressing short hairpin RNAs (shRNAs) against ADGRL4 transcripts offer a potent strategy to inhibit cancer metastasis. These vectors leverage tissue-specific promoters—such as the Tie2 enhancer—to restrict ADGRL4 silencing to tumor-associated vasculature. In orthotopic breast cancer models, systemic AAV9-shADGRL4 administration decreased lung metastasis incidence by 45% within four weeks. Creative Biolabs' biodistribution-optimized AAV serotypes ensure maximal target engagement while minimizing off-tissue effects.
Creative Biolabs offers comprehensive and innovative services to drive the development of ADGRL4 cell therapy. Please for more services.
CAR-T Cells Engineered with ADGRL4-Specific scFv Domains
Creative Biolabs offers CAR-T cell engineering services. Chimeric antigen receptor (CAR)-T cells targeting ADGRL4's extracellular domain show promise in treating vascular-rich solid tumors. By integrating single-chain variable fragments (scFvs) isolated from high-affinity monoclonal antibodies, these CAR-T cells selectively lyse ADGRL4-overexpressing tumor vasculature. In glioblastoma models, intravenously infused ADGRL4-CAR-T cells penetrated the blood-brain barrier and reduced tumor volume by 72% within 14 days. Creative Biolabs' hybridoma development platforms enable rapid scFv generation against conformationally intact ADGRL4 epitopes. Contact our immuno-oncology team to tailor ADGRL4-directed CAR constructs for your clinical needs.
Mesenchymal Stem Cells (MSCs) as ADGRL4 Antagonist Delivery Vehicles
Creative Biolabs offers MSCs as ADGRL4 antagonist delivery vehicles development services. Genetically modified MSCs secreting ADGRL4-neutralizing antibodies offer a dual mechanism: localized anti-angiogenic effects and tumor microenvironment modulation. These cells, transfected with hypoxia-inducible expression cassettes, release therapeutic payloads preferentially within tumor niches. In pancreatic adenocarcinoma cohorts, MSC-delivered ADGRL4 antagonists reduced microvessel density by 58% and enhanced chemotherapy penetration. Creative Biolabs' lentiviral transduction protocols achieve >90% MSC transfection efficiency without compromising viability. Schedule a consultation to integrate ADGRL4-targeting MSC platforms into your cell therapy pipeline.
The therapeutic potential of ADGRL4 modulation demands precision tools and multidisciplinary collaboration. Creative Biolabs' vertically integrated platforms streamline preclinical validation and regulatory compliance. Please feel free to to design bespoke ADGRL4 gene or cell therapy strategies aligned with your clinical objectives. Explore our whitepapers on angiogenesis biomarkers or schedule a capabilities webinar to discover how 20+ years of protein engineering excellence can de-risk your development timeline.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
